Anti–PD-1 Therapy for Patients with Advanced Cholangiocarcinoma: Ready for Prime Time?

Podobne zapisy

• Efficacy and safety of hepatic arterial infusion chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors versus systemic chemotherapy plus lenvatinib and PD-1/PD-L1 inhibitors in advanced unresectable cholangiocarcinoma: a retrospective cohort study
  od: Zhenzhen Zhang, i wsp.
  Wydane: (2025-12-01)
• Efficacy and safety outcomes of PD-1/PD-L1 inhibitors in recurrent cholangiocarcinoma: a real-world, multicenter and retrospective study
  od: Lihui Lin, i wsp.
  Wydane: (2025-07-01)
• Efficacy of PD-1/PD-L1 inhibitors combined with multi-targeted anti-angiogenic TKIs in advanced or metastatic NSCLC: A meta-analysis based on RCTs
  od: Zeqi Tang, i wsp.
  Wydane: (2026-04-01)
• The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study
  od: Yingxiao Cai, i wsp.
  Wydane: (2025-02-01)
• Conversion therapy for unresectable intrahepatic cholangiocarcinoma using gemcitabine plus S-1 combined with PD-1 inhibitors: a case report
  od: Shuangying Zhao, i wsp.
  Wydane: (2025-01-01)